United Capital Financial Advisors LLC Purchases Shares of 24,033 Stryker Corporation $SYK

United Capital Financial Advisors LLC purchased a new stake in Stryker Corporation (NYSE:SYK) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 24,033 shares of the medical technology company’s stock, valued at approximately $7,567,000.

Other hedge funds have also modified their holdings of the company. Varma Mutual Pension Insurance Co grew its position in shares of Stryker by 10.5% in the 4th quarter. Varma Mutual Pension Insurance Co now owns 53,610 shares of the medical technology company’s stock valued at $18,842,000 after acquiring an additional 5,100 shares during the period. QRG Capital Management Inc. increased its position in Stryker by 7.4% during the fourth quarter. QRG Capital Management Inc. now owns 60,548 shares of the medical technology company’s stock worth $21,281,000 after buying an additional 4,186 shares during the last quarter. Swedbank AB increased its holdings in shares of Stryker by 6.6% during the 4th quarter. Swedbank AB now owns 129,027 shares of the medical technology company’s stock worth $45,349,000 after acquiring an additional 7,934 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in Stryker by 31.1% in the 4th quarter. Crossmark Global Holdings Inc. now owns 26,820 shares of the medical technology company’s stock valued at $9,426,000 after acquiring an additional 6,367 shares during the period. Finally, Royal Bank of Canada raised its stake in Stryker by 6.5% in the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after acquiring an additional 199,863 shares during the period. 77.09% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on SYK. Wolfe Research downgraded shares of Stryker from an “outperform” rating to a “peer perform” rating in a report on Thursday, August 13th. BMO Capital Markets began coverage on shares of Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target on the stock. Needham & Company LLC reduced their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of Stryker in a research note on Friday, July 31st. Finally, Truist Financial lifted their price target on Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the transaction, the director directly owned 2,301,375 shares in the company, valued at approximately $773,031,862.50. The trade was a 11.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Dylan Bram Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the sale, the insider owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 over the last quarter. 4.60% of the stock is owned by corporate insiders.

Stryker Stock Down 2.3%

Shares of SYK opened at $322.20 on Friday. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The firm’s 50 day moving average is $328.64 and its 200-day moving average is $331.47. The stock has a market capitalization of $123.58 billion, a PE ratio of 33.39, a P/E/G ratio of 2.10 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the prior year, the business posted $3.13 earnings per share. The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.